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Although hypothalamic glucose sensing is a long-established phenomenon, its physiological role
remains unclear. New studies (Parton et al., 2007; Claret et al., 2007) disrupting glucose sensing in
pro-opiomelanocortin neurons via differing methods have yielded disparate energy and glucose
homeostasis phenotypes, suggesting that neuronal glucose sensing is not critical for these
processes.Since Jean Mayer proposed that
feeding is regulated by hypothalamic
neurons that can sense blood glucose
levels (Mayer, 1953) and the discovery
of these glucose-sensing neurons by
Oomura et al. (1964), many investiga-
tors have tried to forge a definitive
link between neuronal glucose sensing
and a variety of in vivo physiological
functions. Two recent papers (Claret
et al., 2007; Parton et al., 2007)
address this issue using molecular
techniques to selectively alter glucose
sensing in hypothalamic pro-opiome-
lanocortin (POMC) and neuropeptide
Y (NPY)/agouti-related peptide (AgRP)
neurons. Unfortunately, despite the
elegance of their manipulations and
the somewhat unexpected pheno-
types of the resulting animals, we still
cannot connect neuronal glucose
sensing directly to the in vivo regula-
tion of either energy or glucose
homeostasis.
Whereas all neurons require glu-
cose to fuel their metabolic demands,
glucose-sensing neurons also utilize
glucose as a signaling molecule to
regulate their membrane potential
and firing rate (Ashford et al., 1990;
Levin et al., 2004; Oomura et al.,
1964). In specific hypothalamic and
other forebrain and hindbrain sites,
10%–30% of the neurons are glucose
sensing and are linked together as
a distributed network. Many glucose-
sensing neurons also respond to and
integrate signals from other metabo-
lites such as lactate and fatty acids,
and hormones such as leptin and insu-252 Cell Metabolism 6, October 2007 ª2lin (Claret et al., 2007; Levin et al.,
2004; Parton et al., 2007). In addition
to the ability to import and metabolize
glucose to meet their metabolic
demands, glucose-sensing neurons
also possess unique transporters,
enzymes, and ion channels that gate
the metabolism of glucose to regulate
transducers that control membrane
potential. In neurons and astrocytes,
the a2 subunit of AMP-activated
protein kinase (AMPK) is an energy
sensor that serves as one of these
gating mechanisms (Escartin et al.,
2007; Minokoshi et al., 2004). When
glucose availability declines, AMP
levels rise and activate AMPK, which
then acts on currently unidentified
transducers to alter neuronal activity.
Although it has not been associated
with AMPK activation in neurons, the
ATP-activated K+ (KATP) channel is an
important signal transducer in some
glucose-sensing neurons. In these
neurons, the KATP channel is inacti-
vated when glucose metabolism in-
creases the ATP/ADP ratio, leading to
membrane depolarization and neuro-
nal activation (Ashford et al., 1990).
However, KATP channel activity, like
that of AMPK (Minokoshi et al., 2004),
also can be altered by a number of
other convergent signaling pathways
that are independent of glucose
metabolism (Levin et al., 2004). Unlike
AMPKa2, which has a relatively
restricted anatomical distribution, the
KATP channel is ubiquitously ex-
pressed in many neurons (Levin et al.,
2004). Thus, only those neurons with007 Elsevier Inc.a specific gating mechanism linking
the amount of available glucose
directly to the ATP/ADP ratio can
utilize the KATP channel to mediate
glucose sensing.
As might be expected from their crit-
ical roles in the regulation of energy and
glucose homeostasis, arcuate hypo-
thalamic POMC and NPY/AgRP neu-
rons are glucose sensors. Some
POMC neurons utilize AMPK (Claret
et al., 2007) and the KATP channel (Par-
ton et al., 2007) to increase their activity
when glucose levels rise. NPY/AgRP
neurons may be either activated (Claret
et al., 2007) or inhibited (Fioramonti
et al., 2007; Levin et al., 2004) by rising
glucose levels. However, in neither
case do they utilize the KATP channel
to sense glucose. Parton et al. (2007)
rendered POMC neurons unrespon-
sive to glucose by mutating the Kir6.2
subunit of their KATP channels. Claret
et al. (2007) disrupted both POMC
and AgRP neuronal glucose sensing
by deleting AMPKa2. While both strat-
egies similarly perturbed POMC neuro-
nal glucose sensing, the resultant
transgenic animals had very different
in vivo phenotypes (Table 1). The
POMC AMPKa2 mutants had normal
glucose tolerance and ad libitum food
intake but reduced resting energy ex-
penditure. As a result, they became
more obese than wild-type mice on ei-
ther low- or high-fat diets. On the other
hand, mice with dysfunctional KATP
channels in POMC neurons had aber-
rant glucose tolerance but normal
body weight regulation.
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AgRP
AMPKa2KO
POMC
AMPKa2KO POMC-mut-Kir6.2
In vitro
Biophysical properties N N HP
Glucose response NR NR NR
WT glucose sensing type GE GE GE
a-MSH release in response
to glucose alterations
  NR
Leptin response WT NR WT DP WT DP
KO  KO DP mut DP
Insulin response WT DP WT HP WT 
KO DP KO HP mut 
In vivo
Ad libitum food intake N N 
Refeeding food intake N [ 
Leptin-induced anorexia N N 
Resting metabolic rate N Y 
Brown adipose tissue UCP1  Y 
Physical activity N N 
Body weight gain, LFD Y [ N
% fat, LFD  [ N
Body weight gain, HFD N [ 
% fat, HFD  [ 
Glucose excursion on i.p. GTT N N [
Insulin tolerance N N 
Summary of findings from Claret et al. (2007), in which AMPKa2 was deleted
(AMPKa2KO) from either AgRP or POMC neurons, and Parton et al. (2007), in which
the Kir6.2 subunit of the KATP channel was mutated in POMC neurons (POMC-
mut-Kir6.2). N = normal, HP = hyperpolarized, NR = no response, GE = glucose
excited,  = not measured, DP = depolarized, [ = increased as compared to WT,
Y = decreased. WT = wild-type, KO = knockout, mut = mutant. LFD = low-fat diet,
HFD = high-fat diet, i.p. GTT = intraperitoneal glucose tolerance test.Importantly, despite defective glu-
cose sensing produced by altering
KATP channel function or deleting
AMPKa2, neuronal insulin and leptin
responsiveness was preserved, as
were in vivo anorectic responses to
leptin. These results were surprising
since both leptin and insulin alter
KATP channel function in glucose-
excited neurons (Levin et al., 2004)
and since leptin’s anorectic effect is
markedly attenuated in mice that be-
come hyperphagic and obese after
constitutive activation of mediobasal
hypothalamic AMPKa2 (Minokoshi
et al., 2004). However, leptin-induced
anorexia was still preserved whenmediobasal hypothalamic AMPKa2
was inactivated, just as it was when
AMPKa2 was deleted from either
POMC or AgRP neurons (Claret et al.,
2007). Thus, while AMPKa2 activation
is a potent stimulant of feeding that is
not fully antagonized by a single dose
of leptin, it does not appear that
AMPKa2 is required for leptin’s
actions.
Taken together, these studies
(Claret et al., 2007) (Parton et al.,
2007) provide important new insights
into the roles of AMPK and the KATP
channel in neuronal glucose sensing
and the ability of such neurons to
respond to leptin and insulin. First,Cell Metabolismsince disrupting POMC glucose sens-
ing by two independent methods
altered either energy homeostasis or
glucose homeostasis but not both, it
is unlikely that glucose sensing in
POMC neurons is required for the reg-
ulation of either of these functions.
Rather, the disparate phenotypes
likely either are caused by specific
characteristics of AMPKa2 and KATP
channels within POMC neurons, inde-
pendent of glucose sensing, or are
due to their altered function in the
germ cells leading to compensatory
changes in the development of these
neurons. Also, while POMC neuronal
glucose sensing became defective in
obese animals (Parton et al., 2007),
the inverse was not true, as might be
expected if defective POMC neuronal
glucose sensing were a critical predis-
posing cause of obesity. Second, it is
now clear that, like glucokinase (Levin
et al., 2004), AMPKa2 is an impor-
tant mediator of glucose sensing in
both glucose-excited (Claret et al.,
2007) and glucose-inhibited neurons
(Mountjoy et al., 2007). Third, the regu-
lation of food intake, with the excep-
tion of minor abnormalities in refeeding
after fasting (Claret et al., 2007), is
independent of glucose sensing in
either POMC or AgRP neurons. Finally,
not all investigators agree with Claret
et al. (2007) and Parton et al. (2007)
that POMC neurons are capable of
sensing glucose or that NPY/AgRP
neurons are glucose excited (Fiora-
monti et al., 2007; Levin et al., 2004).
Such disparate findings may be a
function of the considerable heteroge-
neity among arcuate POMC and NPY/
AgRP neurons. Further exploration of
the underpinnings of this diversity is
likely to provide new insights into the
manner in which POMC and NPY/
AgRP neurons modulate physiological
function.
Clearly, neuronal glucose sensing is
an important mediator of feeding and
counterregulatory responses to insulin-
induced hypoglycemia (Levin et al.,
2004). However, during the normal
diurnal cycle, hypothalamic glucose
levels are approximately 0.7–2.5 mM,
only 15%–25% of blood levels (de
Vries et al., 2003). Most investigators
have used glucose concentrations
far outside of this range to produce6, October 2007 ª2007 Elsevier Inc. 253
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Previewsfeeding or satiation or to assess the
ability of glucose to alter neuronal
activity or the release of peptides
(Levin et al., 2004; Parton et al., 2007).
Such nonphysiological glucose levels
provide little useful evidence foraphys-
iological role of glucose in vitro or
in vivo in the regulation of neuronal
function or energy and glucose ho-
meostasis. Thus, after more than 50
years, we are still in search of a direct
link between neuronal glucose sensing
and the physiological regulation of
food intake and other facets of energy
and glucose homeostasis. However,
the Claret et al. (2007) and Parton
et al. (2007) studies do point to im-
portant glucose-sensing-independent
roles for both AMPK and the KATPEstrogen and Bo
Center Stage
Deborah V. Novack1,*
1Department of Internal Medicine and Dep
Washington University School of Medicine
*Correspondence: novack@wustl.edu
DOI 10.1016/j.cmet.2007.09.007
Loss of estrogen atmenopause ca
target in this process has remaine
et al., 2007) selectively ablate es
directly induces osteoclast apop
Estrogen plays a central role in the
control of bone strength, and its loss
at menopause causes osteoporosis
in millions of women. In healthy indi-
viduals, bone mass is maintained by
the balanced activity of bone-forming
osteoblasts and bone-resorbing oste-
oclasts. These two cell types, although
derived from mesenchymal and he-
matopoietic precursors, respectively,
affect each other’s differentiation and
activity. In addition, bone, particularly
the trabecular component closely as-
sociated with bone marrow, is a rich
microenvironment in which many cell
types have the opportunity to influence
osteoblast/osteoclast dynamics.
254 Cell Metabolism 6, October 2007 ª2channel in POMC neurons in the con-
trol of these physiological processes,
which should be the focus of future
studies in this field.
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Most estrogenic effects are medi-
ated by the nuclear hormone receptor
transcription factors estrogen receptor
a and b (ERa and b); some actions are
attributed to an unidentified mem-
brane receptor that signals through
JNK or ERK kinases. Mice lacking
ERa, ERb, or both do not show the
expected low bone mass but have
abnormally high levels of either testos-
terone or estradiol, leading to con-
founding effects on the androgen
receptor (Sims et al., 2002). Further
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